Blood Reviews
Volume 19, Issue 2 , Pages 111-123 , March 2005

Platelet function analysis

References 

  1. George JN. Platelets. Lancet. 2000;355:1531–1539
  2. Michelson AD. Platelets. San Diego: Academic Press; 2002;
  3. Rodgers GM. Overview of platelet physiology and laboratory evaluation of platelet function. Clin. Obstet. Gynecol. 1999;42:349–359
  4. Ruggeri ZM. Platelets in atherothrombosis. Nat. Med. 2002;8:1227–1234
  5. Peerschke EI. The laboratory evaluation of platelet dysfunction. Clin. Lab. Med. 2002;22:405–420
  6. Thiagarajan P, Wu KK. In vitro assays for evaluating platelet function. In:  Gresele P,  Page C,  Fuster V,  Vermylen J editor. Platelets in thrombotic and non-thrombotic disorders. Cambridge: Cambrige University Press; 2002;p. 459–470
  7. Rand ML, Leung R, Packham MA. Platelet function assays. Transfus. Apheresis Sci. 2003;28:307–317
  8. Tsiara S, Elisaf M, Jagroop IA, Mikhailidis DP. Platelets as predictors of vascular risk: is there a practical index of platelet activity. Clin. Appl. Thromb. Hemost. 2003;9:177–190
  9. de Gaetano G. A new blood corpuscle: an impossible interview with Giulio Bizzozero. Thromb. Haemost. 2001;86:973–979
  10. Celi A, Merrill-Skoloff G, Gross P, et al.  Thrombus formation: direct real-time observation and digital analysis of thrombus assembly in a living mouse by confocal and widefield intravital microscopy. J. Thromb. Haemost. 2003;1:60–68
  11. Harrison P. Progress in the assessment of platelet function. Br. J. Haematol. 2000;111:733–744
  12. Guidelines on platelet function testing. The British Society for Haematology BCSH Haemostasis and Thrombosis Task Force. J. Clin. Pathol. 1988;41:1322–1330
  13. McKenzie ME, Gurbel PA, Levine DJ, Serebruany VL. Clinical utility of available methods for determining platelet function. Cardiology. 1999;92:240–247
  14. Yamamoto J, Yamashita T, Ikarugi H, et al.  Gorog thrombosis test: a global in-vitro test of platelet function and thrombolysis. Blood Coagul. Fibrin. 2003;14:31–39
  15. Li CK, Hoffmann TJ, Hsieh PY, Malik S, Watson WC. The Xylum clot signature analyzer: a dynamic flow system that simulates vascular injury. Thromb. Res. 1998;92:S67–S77
  16. Li CK, Hoffmann TJ, Hsieh PY, Malik S, Watson W. Xylum CSA: automated system for assessing hemostasis in simulated vascular flow. Clin. Chem. 1997;43:1788–1790
  17. Kundu SK, Heilmann EJ, Sio R, et al.  Description of an in vitro platelet function analyzer – PFA-100. Semin. Thromb. Hemost. 1995;21(Suppl 2):106–112
  18. Gorog DA, Kovacs IB. Thrombotic status analyser. Measurement of platelet-rich thrombus formation and lysis in native blood. Thromb. Haemost. 1995;73:514–520
  19. Varon D, Savion N. Cone and Plate(let) Analyzer. In:  Michelson AD editors. Platelets. San Diego: Academic Press; 2004;p. 337–345
  20. Coiffic A, Cazes E, Janvier G, et al.  Inhibition of platelet aggregation by abciximab but not by aspirin can be detected by a new point-of-care test, the hemostatus. Thromb. Res. 1999;95:83–91
  21. Carr ME. Development of platelet contractile force as a research and clinical measure of platelet function. Cell Biochem. Biophys. 2003;38:55–78
  22. Ozaki Y, Satoh K, Yatomi Y, et al.  Detection of platelet aggregates with a particle counting method using light scattering. Anal. Biochem. 1994;218:284–294
  23. Steinhubl SR, Keriakes DJ. Ultegra rapid platelet function analyzer. In:  Michelson AD editors. Platelets. San Diego: Academic Press; 2004;p. 317–323
  24. Schmitz G, Rothe G, Ruf A, et al.  European Working Group on clinical cell analysis: consensus protocol for the flow cytometric characterisation of platelet function. Thromb. Haemost. 1998;79:885–896
  25. Michelson AD. Flow cytometry: a clinical test of platelet function. Blood. 1996;87:4925–4936
  26. Michelson AD, Barnard MR, Krueger LA, Frelinger AL, Furman MI. Flow cytometry. In:  Michelson AD editors. Platelets. San Diego: Academic Press; 2002;p. 297–315
  27. Michelson AD. How platelets work: platelet function and dysfunction. J. Thromb. Thrombolysis. 2003;16:7–12
  28. George JN, Shattil SJ. The clinical importance of acquired abnormalities of platelet function. N Engl. J. Med. 1991;324:27–39
  29. Kottke-Marchant K, Corcoran G. The laboratory diagnosis of platelet disorders. Arch. Pathol. Lab. Med. 2002;126:133–146
  30. Drachman JG. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood. 2004;103:390–398
  31. Budde U, Schneppenheim R. Von Willebrand factor and von Willebrand disease. Rev. Clin. Exp. Hematol. 2001;5:335–368
  32. Cattaneo M. Inherited platelet-based bleeding disorders. J. Thromb. Haemost. 2003;1:1628–1636
  33. Michelson AD. The clinical approach to disorders of platelet number and function. In:  Michelson AD editors. Platelets. San Diego: Academic Press; 2002;p. 541–545
  34. Lind SE. The bleeding time. In:  Michelson AD editors. Platelets. San Diego: Academic Press; 2002;p. 283–289
  35. Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin. Thromb. Hemost. 1990;16:1–20
  36. Elwood PC, Pickering J, Yarnell J, et al.  Bleeding time, stroke and myocardial infarction: the Caerphilly prospective study. Platelets. 2003;14:139–141
  37. Refaai MA, Laposata M. Platelet aggregation. In:  Michelson AD editors. Platelets. San Diego: Academic Press; 2004;p. 291–296
  38. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J. Lab. Clin. Med. 2001;138:152–163
  39. Francis JL. Platelet Function Analyzer (PFA-100). In:  Michelson AD editors. Platelets. San Diego: Academic Press; 2004;p. 325–335
  40. Favaloro EJ. Utility of the PFA-100 for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations. Haemophilia. 2001;7:170–179
  41. Posan E, McBane RD, Grill DE, Motsko CL, Nichols WL. Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice. Thromb. Haemost. 2003;90:483–490
  42. Fressinaud E, Veyradier A, Truchaud F, et al.  Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood. 1998;91:1325–1331
  43. Favaloro EJ. Clinical application of the PFA-100. Curr. Opin. Hematol. 2002;9:407–415
  44. Cariappa R, Wilhite TR, Parvin CA, Luchtman-Jones L. Comparison of PFA-100 and bleeding time testing in pediatric patients with suspected hemorrhagic problems. J. Pediatr. Hematol. Oncol. 2003;25:474–479
  45. Fattorutto M, Pradier O, Schmartz D, Ickx B, Barvais L. Does the platelet function analyser (PFA-100) predict blood loss after cardiopulmonary bypass?. Br. J. Anaesth. 2003;90:692–693
  46. Chakroun T, Gerotziafas G, Robert F, et al.  In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br. J. Haematol. 2004;124:80–85
  47. Alberts MJ, Bergman DL, Molner E, et al.  Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke. 2004;35:175–178
  48. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb. Res. 2002;108:37–42
  49. Macchi L, Christiaens L, Brabant S, et al.  Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb. Res. 2002;107:45–49
  50. Gum PA, Kottke-Marchant K, Poggio ED, et al.  Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. Cardiol. 2001;88:230–235
  51. Varon D, Dardik R, Shenkman B, et al.  A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions. Thromb. Res. 1997;85:283–294
  52. Smith JW, Steinhubl SR, Lincoff AM, et al.  Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation. 1999;99:620–625
  53. Kereiakes DJ, Mueller M, Howard W, et al.  Efficacy of abciximab induced platelet blockade using a rapid point of care assay. J. Thromb. Thrombolysis. 1999;7:265–276
  54. Wang JC, Aucoin-Barry D, Manuelian D, et al.  Incidence of aspirin nonresponsiveness using the Ultegra rapid platelet function assay – ASA. Am. J. Cardiol. 2003;92:1492–1494
  55. Malinin AI, Atar D, Callahan KP, McKenzie ME, Serebruany VL. Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease. Eur. J. Pharmacol. 2003;462:139–143
  56. Carr ME, Martin EJ, Kuhn JG, Spiess BD. Onset of force development as a marker of thrombin generation in whole blood: the thrombin generation time (TGT). J. Thromb. Haemost. 2003;1:1977–1983
  57. Greilich PE, Carr ME, Zekert SL, Dent RM. Quantitative assessment of platelet function and clot structure in patients with severe coronary artery disease. Am. J. Med. Sci. 1994;307:15–20
  58. Carr ME. Diabetes mellitus: a hypercoagulable state. J. Diabetes Complicat. 2001;15:44–54
  59. Carr ME, Martin EJ, Kuhn JG, Seremetis SV. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion. Thromb. Haemost. 2003;89:803–811
  60. Nicholson NS, Panzer-Knodle SG, Haas NF, et al.  Assessment of platelet function assays. Am. Heart J. 1998;135:S170–S178
  61. Mobley JE, Bresee SJ, Wortham DC, et al.  Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am. J. Cardiol. 2004;93:456–458
  62. Michelson AD, Furman MI. Laboratory markers of platelet activation and their clinical significance. Curr. Opin. Hematol. 1999;6:342–348
  63. Cohn RJ, Sherman GG, Glencross DK. Flow cytometric analysis of platelet surface glycoproteins in the diagnosis of Bernard-Soulier syndrome. Pediatr. Hematol. Oncol. 1997;14:43–50
  64. Lindahl TL, Lundahl J, Netre C, Egberg N. Studies of the platelet fibrinogen receptor in Glanzmann patients and uremic patients. Thromb. Res. 1992;67:457–466
  65. Billio A, Moeseneder C, Donazzan G, et al.  Hermansky-Pudlak syndrome: clinical presentation and confirmation of the value of the mepacrine-based cytofluorimetry test in the diagnosis of delta granule deficiency. Haematologica. 2001;86:220
  66. Wall JE, Buijs-Wilts M, Arnold JT, et al.  A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents. Br. J. Haematol. 1995;89:380–385
  67. Gordon N, Thom J, Cole C, Baker R. Rapid detection of hereditary and acquired platelet storage pool deficiency by flow cytometry. Br. J. Haematol. 1995;89:117–123
  68. Vidal C, Spaulding C, Picard F, et al.  Flow cytometry detection of platelet procoagulation activity and microparticles in patients with unstable angina treated by percutaneous coronary angioplasty and stent implantation. Thromb. Haemost. 2001;86:784–790
  69. Solum NO. Procoagulant expression in platelets and defects leading to clinical disorders. Arterioscler. Thromb. Vasc. Biol. 1999;19:2841–2846
  70. McRedmond JP, Park SD, Reilly DF, et al.  Integration of proteomics and genomics in platelets: a profile of platelet proteins and platelet-specific genes. Mol. Cell Proteomics. 2004;3:133–144
  71. Bugert P, Dugrillon A, Gunaydin A, Eichler H, Kluter H. Messenger RNA profiling of human platelets by microarray hybridization. Thromb. Haemost. 2003;90:738–748
  72. Gnatenko DV, Dunn JJ, McCorkle SR, et al.  Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood. 2003;101:2285–2293
  73. Garcia A, Prabhakar S, Hughan S, et al.  Differential proteome analysis of TRAP-activated platelets: involvement of DOK-2 and phosphorylation of RGS proteins. Blood. 2004;103:2088–2095
  74. Garcia A, Prabhakar S, Brock CJ, et al.  Extensive analysis of the human platelet proteome by two-dimensional gel electrophoresis and mass spectrometry. Proteomics. 2004;4:656–668
  75. Maguire PB, Fitzgerald DJ. Platelet proteomics. J. Thromb. Haemost. 2003;1:1593–1601

PII: S0268-960X(04)00031-1

doi: 10.1016/j.blre.2004.05.002

Blood Reviews
Volume 19, Issue 2 , Pages 111-123 , March 2005

Article Tools

* Image Usage & Resolution